by Madaline Spencer | Nov 20, 2024
Emily Milligan, Executive Director of The Barth Syndrome Foundation, discusses the U.S. Food and Drug Administration’s (FDA) recommendation of approval for Barth syndrome treatment, elamipretide. Barth syndrome is a rare metabolic and neuromuscular...
by Madaline Spencer | Nov 19, 2024
Marc Elia, Chairman of the Board of Directors at Invivyd, discusses Pemgarda (pemivibart) for emergency use as a pre-exposure prophylactic therapy for prevention of COVID-19 infection in patients with compromised immune systems. As Mr. Elia explains,...
by Madaline Spencer | Nov 18, 2024
James F. Howard, Jr., MD, The University of North Carolina at Chapel Hill, discusses the interim analysis of the RAISE-XT extension study for myasthenia gravis (MG). MG is a chronic autoimmune neuromuscular disease characterized by weakness of the...
by Madaline Spencer | Nov 15, 2024
X4 Pharmaceuticals announced positive results from their phase 2 clinical trial for mavorixafor in chronic neutropenia. Chronic neutropenic disorders are blood conditions characterized by low levels of neutrophils. These disorders are associated with...
by Madaline Spencer | Nov 15, 2024
Tuan Vu, MD, Professor of Neurology at the University of South Florida, discusses positive results in Vivacity-MG3 study evaulating the safety and efficacy of nipocalimab for myasthenia gravis (MG). MG is a chronic autoimmune neuromuscular disease...
